Japan Continues Safety Policy Limiting Teenage Use Of Tamiflu
This article was originally published in PharmAsia News
Executive SummaryThe Drug Safety Committee at the Pharmaceutical and Food Sanitization Council of Japan's Ministry of Health, Labor and Welfare June 16 decided to continue its current safety measure of limiting Tamiflu (oseltamivir) use in minors over 10 years of age. The committee's decision was based on two working group's scientific and clinical findings, which noted that although there was no statistical significance between Tamiflu users and non-users in the age group, the users had 1.54 times higher risk of developing abnormal behavior. The groups also stated that the research couldn't establish a casual relationship between taking Tamiflu and abnormal behavior. The safety policy was initiated in March 2007 when the Ministry received reports of teenagers showing abnormal behaviors after taking Tamiflu. (Click here for more - Japanese Language
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.